|
Found 90 result(s) FROM 1963 pages containing the term 'IL-1'.
Wednesday Jan 27, 2010
RA Development Can Be Predicted by Inflammatory Cytokines
Increased concentrations of proinflammatory cytokines can predict onset of RA before symptoms develop...
Wednesday Sep 30, 2009
FDA Finally OKs Stelara for Psoriasis
The FDA has approved Centocor's Stelara (ustekinumab) for moderate to severe psoriasis...
Tuesday Sep 08, 2009
RA Drug Array ARRY-162 Fails in Phase 2
A new rheumatoid drug from Array BioPharma that modulates the MEK pathway did not meet Phase 2 efficacy goals...
Thursday Jul 16, 2009
Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
The pan-cytokine inhibitor ARRY-797 was safe at doses of up to 1,200 mg/day in a phase 1 dose-escalation study in RA patients, but will not be developed further for use in RA...
Tuesday Jul 07, 2009
Quercetin Boosts Exercise Capacity
New research shows that quercetin supplementation boosts endurance and maximal oxygen capacity in healthy, active but untrained men and women...
Monday Jun 22, 2009
IL-Blockade with Canakinumab Effective, Safe in JIA
Phase II data show that canakinumab (ACZ885) seems effective and safe in children with systemic juvenile idiopathic arthritis...
Friday Mar 20, 2009
"Inner Space" Debris Triggers Joint Implant Failure
Immune reactions to metal debris from joint replacements triggers immune-mediated joint failure...
Wednesday Feb 18, 2009
Ustekinumab Reduces Psoriatic Arthritis Pain, Clears Lesions
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23 (IL-23), may help thwart the pain, swelling and lesions of psoriatic arthritis...
Wednesday Feb 04, 2009
Anakinra Shows Modest Benefit, Some Risk in RA: Cochrane Review
The IL-1 receptor antagonist Anakinra (Kineret, Amgen) significantly improves rheumatoid arthritis (RA) patients but may be less effective than other biologicals...
Tuesday Nov 25, 2008
Who Stays in RA Remission After TNF Blockade Stops?
Patients who start treatment soon after RA symptoms appear, and who have increased functional T-cells, higher levels of interleukin-10, and lower levels of interleukin-12 maintain sustained remission even after stopping TNF-blockers...
Wednesday Nov 12, 2008
Novartis’ ACZ885 Phase III Data Show Rapid, Sustained Clinical Remission in Children and Adults with CAPS, a Group of Rare, Potentially Life-Threatening Autoinflammatory Diseases
Novartis also announced that preliminary results of a phase I/II study in systemic juvenile idiopathic arthritis showed that most patients treated with ACZ885 achieved substantial clinical improvement within 15 days...
Wednesday Oct 08, 2008
Fractalkine May Be Key to Unleashed Immune Response in Rheumatoid Arthritis
Fractalkine (FKN) is emerging as a central player in the RA synovial inflammation, neovascularization, and joint destruction, and also might be link between joint damage and increased cardiovascular risk...
Wednesday Sep 10, 2008
Arcalyst® (rilonacept) Reduced Gout Flares by 81% in a Phase II Study Initiating Urate-Lowering Therapy
Based upon these results, a phase III clinical development program will be initiated early in 2009 with Arcalyst in the prevention of gout flares in patients initiating urate-lowering drug therapy...
Monday Sep 08, 2008
ACR Research and Education Foundation Grants Point to New Arthritis Research
New REF grants target RA immunotherapy, inflammation, bone erosions, PAD inhibition...
Monday Aug 11, 2008
Hollis-Eden Initiates Phase I/II Clinical Trial With TRIOLEX™ (HE3286) in RA
Hollis-Eden's investigational, nonimmunosuppressive oral drug candidate Triolex™ (HE3286), a stabilized, synthetic analog of a naturally occurring molecule metabolized by the body, is being tested in patients diagnosed with RA who are receiving a stable dose of MTX...
Tuesday Jul 22, 2008
Compugen Reports Positive Preclinical Results for Therapeutic Peptide Candidate for Immune Related Diseases
The gp96 protein triggers both the innate and adaptive arms of the immune system and is thought to play a key role in inflammatory responses, making it an important target for therapeutic intervention in the treatment of immune-related disorders...
Tuesday Jul 22, 2008
Ardea Biosciences Advances RDEA806 Into Phase IIa Proof-of-Concept Study for Gout
Ardea Biosciences has received regulatory approval to begin a phase IIa proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia...
Friday Jul 11, 2008
MediGene Puts Phase I Trial Hold on Due to Patient Death in Study of RhuDex® in a New Formulation; Reports Positive Results With RhuDex in Phase IIa Pilot Trial in RA
One study participant suffered a heart problem some days after a scheduled treatment of RhuDex®, an orally administered candidate for the treatment of RA; it is currently unclear whether there is any correlation between the death and the drug administration...
Wednesday Jun 18, 2008
Rigel Launches Two Global Phase IIb Clinical Trials of Syk Inhibitor, R788 (fostamatinib disodium), in RA
Rigel currently has small-molecule product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma...
Tuesday May 06, 2008
Rigel's R788 (fostamatinib disodium) Slows Progression, Prolongs Survival in Murine Lupus Model; Phase II Lupus Clinical Trial Planned Later in 2008
Rigel's lead agent, R788 (fostamatinib disodium), an orally bioavailable spleen tyrosine kinase inhibitor, has successfully treated lupus-prone mice and significantly improved their survival...
Friday Mar 28, 2008
Regeneron’s Arcalyst™ (rilonacept), First and Only FDA-Approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS); Now Available in the US
Regeneron Pharmaceuticals, Inc announced that Arcalyst™ (rilonacept) injection for subcutaneous use is now available by prescription in the US for the treatment of cryopyrin-associated periodic syndromes (CAPS)...
Thursday Mar 27, 2008
Anacor’s Phase IIa Psoriasis Trial of AN2728 Achieves Primary, Secondary Endpoints
Anacor Pharmaceuticals, Inc announced positive results from a phase IIa clinical trial of AN2728, a boron-containing inhibitor of phosphodiesterase-4 (PDE4), in patients with psoriasis...
Thursday Feb 14, 2008
Celgene Reports More Positive Phase II Data on Apremilast in Psoriasis Patients; to Expand Dosing Level, Duration; Accelerate Advancement in Psoriasis, Psoriatic Arthritis, RA
Celgene Corp announced positive clinical data from a phase II study of apremilast (CC-10004), its lead orally bioavailable, small molecule inhibitor of TNF/PDE4, in patients with moderate-to-severe plaque psoriasis...
Friday Feb 01, 2008
IL-27 Shows Promise for Treating Inflammatory Arthritis
Interleukin-27 (IL-27) can attenuate collagen-induced arthritis when given early in the disease course by blocking Th17 differentiation...
Tuesday Dec 11, 2007
Identification of Two New Ankylosing Spondylitis Genes Suggest Novel Therapeutic Targets
Genome scans have identified two of the suspected handful of non-MHC genes that appear to collaborate with HLA-B27 in "turning on" disease processes that result in ankylosing spondylitis and other seronegative arthropathies...
Tuesday Nov 13, 2007
Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...
Tuesday Nov 06, 2007
Cytokine PharmaSciences Develops Orally Active Form of Semapimod, a Raf Kinase Inhibitor, for Inflammatory and Autoimmune Diseases; Seeks Partner
Cytokine PharmaSciences Inc, a privately-held, global biopharmaceutical company, announced development of an orally active form of semapimod, its anti-inflammatory cytokine compound...
Monday Oct 22, 2007
Hollis-Eden Reports Positive Data Demonstrating That Anti-Inflammatory Agent HE3286 (TriolexTM) Provides Benefit in Animal Models of Ulcerative Colitis and RA; Will Initiate Phase I/II Clinical Study in RA
Hollis-Eden Pharmaceuticals, Inc, a company focused on the development of a proprietary new class of small molecules that are metabolites or synthetic analogs of endogenous adrenal steroid hormones, announced additional data on drug candidate HE3286 (TriolexTM), an orally active, second generation, synthetic 17-ethynyl derivative of the steroid hormone dehydroepiandrosterone (DHEA), currently in preclinical and clinical study for the treatment of autoimmune diseases and inflammatory disorders...
Thursday Oct 11, 2007
IL-1ra Gene Therapy Stops Intervertebral Disc Degradation, Explant Study Shows
An in vitro study shows that IL-1 receptor antagonist delivered either directly or by gene therapy can inhibit matrix degradation in human intervertebral disc...
Tuesday Oct 09, 2007
Centocor Reports Infrequently-Administered Subcutaneous Injection of Anti-IL-12/23 Antibody, Ustekinumab, Resulted in Long-Term PASI 75 Response in Phase III Study
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced findings from an international, randomized, double-blind, placebo-controlled phase III study involving 1230 subjects...
Friday Oct 05, 2007
Abbott's Anti-IL-12/23 Antibody, ABT-874, Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
Abbott Laboratories announced positive study data from an extension to a phase II study demonstrating that a majority of moderate-to-severe psoriasis patients who responded to anti-IL-12/23 (ABT-874) after 12 weeks of treatment maintained a high level of response at 24 weeks, following discontinuation of therapy...
Friday Oct 05, 2007
Future Looks Bright for Sjögren's Syndrome Patients
B- and T-cell targeted therapies as well as other biologic drugs may change the way primary Sjögren's syndrome is treated in the future...
Wednesday Sep 19, 2007
Anticytokine Shots May Aid Healing Following Knee Injuries
Shooting TNF inhibitors or IL-1 blockers directly into the joint may help promote healing following meniscal tears…McNulty AL, et al. Arthritis Rheum. 2007;56:doi:10.1002/art [Epub ahead of print].
Tuesday Aug 28, 2007
Interleukin Genetics Collaborates With NYU Medical Center to Evaluate Genetic Patterns Associated With IL-1β Overproduction and Development of Polyarticular OA
Interleukin Genetics, a genetics-focused personalized health company, announced today that it has initiated a study on the genetics of osteoarthritis (OA) in collaboration with the Hospital for Joint Diseases of New York University Medical Center...
Thursday Aug 09, 2007
Regeneron's Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS, a Spectrum of Rare Inherited Autoinflammatory Conditions
Regeneron Pharmaceuticals, Inc, announced that the US FDA has accepted for filing and granted priority review status to the Biologics License Application (BLA) for rilonacept (interleukin-1 (IL-1) Trap), a potent, long-acting inhibitor of IL-1, for the long-term treatment of cryopyrin-associated periodic syndromes (CAPS)...
Tuesday Aug 07, 2007
Medarex Announces Initiation by Licensing Partner Novartis of Phase III Clinical Trial for Muckle-Wells Syndrome, a Rare Inherited Autoinflammatory Disease
Medarex, Inc announced that Novartis Pharmaceuticals AG has advanced ACZ885, a fully human monoclonal antibody targeting interleukin-1β (IL-1 β), to a phase III clinical trial for Muckle-Wells syndrome (MWS), an inherited systemic autoinflammatory disease...
Thursday Aug 02, 2007
TNF Inhibitors May Restore Adrenal Function in RA
TNF inhibitors appear to improve adrenal function in some RA patients, resulting in restoration of stable hormonal homeostasis...
Friday Jul 20, 2007
OA Experts Discuss Inflammation, Joint Protection, Need for Disease-Modifying OA Drugs
CIAOMed's roundtable of osteoarthritis experts discuss the role of inflammation in OA, the possibility that OA joint damage might be preventable, and the future role of disease-modifying drugs in OA....
Thursday Jul 19, 2007
ACR REF Campaign Taps Brightest Minds to Cure RA
The American College of Rheumatology Research and Education Foundation has awarded $6 million in grant money to 15 arthritis researchers as part of a new "Within Our Reach: Finding a Cure for Rheumatoid Arthritis" campaign.
Friday Jul 06, 2007
Chi-Med Announces Positive Phase II Data for Botanical Compound, HMPL-004, in Ulcerative Colitis
Chi-Med, the Hutchison Whampoa-backed pharmaceutical and healthcare group, announced positive results for its phase II proof-of-concept study for HMPL-004 in mild-to-moderate ulcerative colitis (UC).
Wednesday Jun 27, 2007
Roche and Toyama Chemical Execute Agreement to Develop and Commercialize an Inhibitor of the Transcription Factor AP-1 (Activator Protein-1) to Treat RA
Roche Pharmaceuticals and Toyama Chemical Co, Ltd announced that they have entered into a licensing agreement for the worldwide research, development, and commercialization of Toyama's rheumatoid arthritis (RA) agent T-5224, an orally bioavailable inhibitor of the transcription factor AP-1 (Activator Protein-1).
Friday Jun 15, 2007
Two Thirds of Gout Patients Receiving No, or Not Enough Treatment
A number of new treatment options for gout are available, but the major clinical problem is that even after gout diagnosis, only about one third of patients receive urate-lowering therapy...
Wednesday May 23, 2007
Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Agents Based on Successful Phase II Trial in Psoriasis; Expands Clinical Program to Include RA and PsA
Celgene Corp (SUMMIT, New Jersey), an integrated global biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies for the treatment of inflammatory diseases and cancer, announced plans to advance its leading oral anti-inflammatory candidates to address a broad range of inflammatory diseases...
Tuesday May 15, 2007
TNF-α, IL-1 Mediate Postmenopausal Osteoporosis
Blocking TNF-α or IL-1 can slow postmenopausal bone loss...
Thursday Apr 26, 2007
Local Gene Therapy for RA Intra-articular Anti-TNF Gene Transduction Reduces Joint Inflammation in RA Animal Model
An anti-TNF gene therapy vector carried by an adeno-associated retrovirus vector and injected into inflamed joints successfully reduced joint inflammation and levels of inflammatory markers in an animal model of RA...
Monday Apr 23, 2007
Rigel Provides Clinical Update of R788 Phase II Trials in ITP and RA
Rigel Pharmaceuticals, Inc, a clinical-stage drug development company, provided an update on R788, currently involved in ongoing phase II clinical trials in immune thrombocytopenic purpura (ITP) and rheumatoid arthritis (RA)...
Monday Apr 09, 2007
Callisto Announces Positive Data for Guanylate Cyclase Receptor Agonist in Animal Models of Ulcerative Colitis, and Intent to Advance Compound into Clinical Trials
Callisto Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company that focuses on cancer and inflammatory bowel disease (IBD), announced data from two different standard animal models of experimental colitis confirming the efficacy of Guanilib (also known as SP304), a first-in-class orally bioavailable mimetic of uroguanylin currently in preclinical development for the treatment of IBD.
Thursday Mar 22, 2007
Clinquest Obtains from TNO Exclusive Worldwide Rights to Develop and Commercialize Protein for Inflammatory Disorders
Clinquest Group (AMSTERDAM, The Netherlands), a provider of product development services to the biopharmaceutical, medical device, diagnostics and medical data industries, and TNO (DELFT, The Netherlands), an independent research technology organization, announced the signing of a license and collaboration agreement that provides Clinquest with the exclusive rights to worldwide clinical development and commercialization of CQ-07001, a human protein shown to be a powerful agonist to toll-like receptor 3 (TLR3) and a candidate for anti-inflammatory and tissue regeneration applications...
Thursday Feb 08, 2007
Centocor Releases Phase II Data on CNTO 1275, a Monoclonal Antibody Targeting IL-12/IL-23, for Chronic Plaque Psoriasis
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that phase II data showed that patients with moderate-to-severe plaque psoriasis who received subcutaneous injections of CNTO 1275 experienced significant clearance of skin disease and significant improvements in quality of life...
Tuesday Feb 06, 2007
New RA Vaccine Targets Regulatory T-Cells
A pilot clinical trial of a new RA vaccine derived from autologous synovial T-cells shows proof-of-principle that inducing CD4+ regulatory T-cells can improve clinical and laboratory parameters in RA patients...
Monday Jan 29, 2007
MediGene Initiates Phase IIa Clinical Trial of RhuDex®, an Oral Inhibitor of T-cell Activation, in RA
MediGene AG (MARTINSRIED/MUNICH, Germany), the publicly-held biotechnology company targeting autoimmune diseases and cancer announced the initiation of a phase IIa clinical trial of its drug candidate RhuDex®, a novel, orally bioavailable inhibitor of T-cell costimulation via the CD80-CD28 pathway, in patients with severe rheumatoid arthritis (RA).
Monday Jan 08, 2007
MedImmune In-Licenses from Japan Tobacco anti-ICOS Monoclonal Antibody for Inflammatory Diseases
MedImmune, Inc announced an exclusive license agreement with Japan Tobacco, Inc (JT), for a human monoclonal antibody inhibiting inducible costimulator (ICOS), a protein associated with T-cell activation that plays a key role in controlling adaptive immune responses.
Wednesday Dec 20, 2006
GlaxoSmithKline and Genmab Enter Exclusive Global Agreement for HuMax-CD20, a B-cell Depletion Agent; Deal Potentially Worth US$2.1 Billion
GlaxoSmithKline plc and Genmab A/S announced a worldwide agreement to codevelop and commercialize HuMax-CD20â„¢ (ofatumumab), a fully human monoclonal IgG1antibody targeting the CD20 antigen on the surface of B cells and currently in phase II clinical trial development for active rheumatoid arthritis (RA), and in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL).
Wednesday Dec 20, 2006
Celera Identifies Genetic Variations in Genes Encoding IL-12 and IL-23 Predisposing Individuals to Increased Risk for Psoriasis
Celera, an Applera Corporation business, announced findings that variants in the genes encoding interleukin-12 (IL12B) and interleukin-23 (IL23R), involved in regulating the behavior of cells of the immune system, independently contribute to psoriasis risk.
Monday Dec 11, 2006
GlaxoSmithKline to Acquire Domantis for US$454 Million
GlaxoSmithKline (LONDON, United Kingdom) announced that it has entered into an agreement to acquire Domantis Ltd (an early-stage, antibody-based therapeutics company) for US$454 million in cash.
Monday Nov 06, 2006
Array BioPharma Reports Success in Two Approaches to Inflammatory Disease: MEK Inhibitor Achieves Phase I Clinical Objectives; p38 MAP Kinase Inhibitor Advances into Clinical Development
Array BioPharma Inc. (BOULDER, Colorado), a biopharmaceutical company focused on the discovery, development, and commercialization of orally active, small molecule drugs for the treatment of inflammatory diseases and cancer, announced preliminary results from a phase I clinical trial evaluating its first-in-class MEK (MAPK kinase) inhibitor for the treatment of inflammatory diseases.
Wednesday Nov 01, 2006
Regeneron's Phase III Clincial Program for Interleukin-1 (IL-1) Trap, a Long Lasting IL-1 Inhibitor, Achieves Primary Endpoints in Studies with Patients Diagnosed with CAPS, a Spectrum of Rare Chronic Autoinflammatory Syndromes
Regeneron Pharmaceuticals, Inc, announced positive data from a phase III clinical program designed to provide two separate demonstrations of efficacy for the investigational drug Interleukin-1 (IL-1) Trap within a single group of patients suffering from CAPS (CIAS1-related Autoinflammatory Periodic Syndromes).
Wednesday Oct 18, 2006
Rigel Selects a Novel JAK3 Inhibitor for Advanced Preclinical Development for Immune-Mediated Diseases
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company focused on small-molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer, and viral diseases, announced that it has selected R348, a potent and selective inhibitor of janus tyrosine kinase 3 (JAK3), to enter preclinical studies to support an investigational new drug application planned for 2007...
Tuesday Sep 05, 2006
Medarex and GenPat77 to Codevelop Humanized Therapeutic Antibodies Against Immune Modulatory Targets
Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products...
Monday Aug 28, 2006
TNF-α Plays a Key Role in Hormone-Related Osteoporosis
Tumor necrosis factor-alpha (TNF-α) is the critical cytokine mediating osteoclast formation and osteoporosis in several types of hormone-related osteoporosis, and TNF inhibitors may have a role to play in osteoporosis prevention and treatment. Hase H, Ando T, Eldeiry L, et al. Proc Nat Acad Sci USA. 2006;103:12849-12854.
Wednesday Aug 16, 2006
Biogen Idec and University of Adelaide Find TWEAK Is a Novel Arthritogenic Mediator; Potential New Pathway in Rheumatoid Arthritis and Osteoarthritis Disease Process
Biogen Idec announced studies published in the August 15, 2006, issue of the providing evidence that TWEAK (TNF-like weak inducer of apoptosis), a TNF family member, is a novel arthritogenic mediator that contributes to joint tissue inflammation, angiogenesis, and destruction, and may inhibit endogenous repair.
Monday Aug 14, 2006
Lower IL-4, IL-10 Levels Seen as Possible Basis for Fibromyalgia Test
New research showing that patients with chronic widespread pain have significantly lower levels of the anti-inflammatory cytokines Interleukin (IL)-4 and IL-10 may help doctors develop a cytokine expression profile that can aid in the diagnosis of fibromyalgia. Üçeyler, N, et al. Arthritis Rheum. 2006;54:2656-2664
Wednesday Jun 21, 2006
Thalidomide, IL-6 Inhibitors Seen As Possible Treatments in JIA
Thalidomide, IL-6 receptor inhibitors, and genomics were highlights of the overview of JIA presented by Patricia Woo, MD, at the 2006 EULAR Meeting...
Wednesday Jun 14, 2006
Arthritis Gene Therapy Inches Forward
TNF inhibitors and other biologicals may command more attention, and stem cells may be more controversial, but arthritis gene therapy continues to move quietly ahead... Evans C, et al. Arthritis Rheum. 2006;54:1714-1729.
Monday Jun 12, 2006
Regeneron's IL-1 Trap Receives Fast-Track Designation From US FDA for CIAS1-Associated Periodic Syndromes (CAPS)
Regeneron's IL-1 Trap has received fast-track designation from the US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases...
Saturday Jun 10, 2006
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Regeneron's IL-1 Trap Receives Fast-Track Designation from US FDA for CIAS1-Associated Periodic Syndromes (CAPS), a family of rare autoinflammatory diseases
Wednesday May 31, 2006
Synta Initiates Phase II Clinical Trials in RA, CVID for Oral Inhibitor of IL-12 and IL-23
Synta Pharmaceuticals Corp announced the dosing of the first patients in its phase IIa clinical studies of apilimod mesylate in RA and CVID...
Wednesday May 24, 2006
Centocor's RemicadeR Approved by US FDA for Pediatric Crohn's Disease
Centocor Inc announced US FDA approval of Remicade® (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease...
Monday Mar 20, 2006
Vertex's Investigational p38 MAP Kinase Inhibitor Meets Primary Objectives in Phase II Trials for RA
Vertex Pharmaceuticals Inc, of Cambridge, Massachusetts, announced that its oral drug candidate, the p38 mitogen-activated protein (MAP) kinase inhibitor VX-702...
Monday Mar 20, 2006
Avidex's T-Cell Co-stimulation Modulator, RhuDex®, Successfully Completes Phase I Trials for RA
Avidex Limited, of Oxford, UK, announced that its lead investigational therapeutic candidate, RhuDex®...
Monday Mar 13, 2006
NPS Receives Approvable Letter From US FDA for Recombinant Human Parathyroid Hormone for Osteoporosis; FDA Expresses Concern Regarding Hypercalcemia
NPS Pharmaceuticals, Inc, of Salt Lake City, Utah, announced that it has received an "approvable letter" from the US Food and Drug Administration (FDA) for their new drug application for PREOS®...
Wednesday Jan 04, 2006
Synta to Advance Clinical Development of IL-12/IL-23 Inhibitor for Crohn's Disease and RA
Synta Pharmaceuticals of Lexington, Massachusetts, announced that it will focus its clinical development efforts in 2006 on STA-5326, an oral interleukin (IL)-12/IL-23 inhibitor...
Tuesday Dec 20, 2005
Research Outlines Novel Role of IL-1, IGF-1 in Cartilage Damage of Arthritis
A new study by Dutch investigators suggests that interleukin-1 (IL-1)-induced suppression of cytokine signaling (SOCS) 3 renders chondrocytes insensitive to insulin-like growth factor-1 (IGF-1), a novel mechanism that appears to contribute to cartilage damage in arthritis...Van der Loo FAJ, et al. Presented at: 10th World Congress of the Osteoarthritis Research Society International (OARSI); December 8–11, 2005; Boston, Mass.
Friday Oct 07, 2005
Novel Population of T Cells Found to Produce IL-17; In Vivo Analysis Reveals Role of Cytokine in Inflammatory Disease
New research examining the production and function of the inflammatory cytokine interleukin 17 (IL-17) may pave the way for more effective ways to prevent and treat rheumatoid arthritis (RA) and other autoimmune and inflammatory conditions . . . Nat Immunol [serial online]. October 2, 2005.
Thursday Oct 06, 2005
Regeneron Discontinues IL-1 Trap Program in Adult RA
Regeneron Pharmaceuticals, Inc (Tarrytown, NY), a biopharmaceutical company with therapeutic candidates in clinical trials for the potential treatment of cancer, age-related eye diseases, and inflammatory diseases, announced...
Wednesday Jun 22, 2005
Phytomedics In-Licenses Anti-Inflammatory Sesquiterpene Lactones
Phytomedics Inc, a Dayton, New Jersey-based developer of novel botanical therapeutics, announced that it has acquired exclusive US licensing rights from Louisiana State University in Baton Rouge for an invention pertaining to sesquiterpene (terpene compounds with 15 carbon atoms) lactones (a cyclic ester) and sesquiterpene lactone-containing plant extracts for the treatment of severe inflammatory disorders such as psoriasis, pemphigus vulgaris, sepsis, and postreperfusion injury.
Friday Jun 17, 2005
Vertex Inhibitor of p38 MAP Kinase Starts Phase II in RA
Vertex Pharmaceuticals Inc has initiated a 3-month Phase II clinical trial of VX-702, an orally administered small molecule inhibitor of p38 mitogen-activated protein (MAP) kinase, for the treatment of rheumatoid arthritis (RA).
Monday Jun 13, 2005
Smokers Have More Active Rheumatoid Arthritis Than Nonsmokers, but Quitting May Help Reduce Disease Severity
New research presented at EULAR increases our understanding of how smoking impacts RA, and emphasizes the symptomatic benefits for those who stop...presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Thursday Jun 09, 2005
Study Helps Clarify Link Between RA and CVD
Il-6, rheumatoid factor, and chronic kidney disease predict endothelial dysfunction among RA patients and need to be suppressed to stave off atherosclerosis...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday May 20, 2005
Study Provides Clues to the Mechanism of Remission of Inflammatory Diseases During Pregnancy
Analysis of pro- and anti-inflammatory cytokines in pregnant women with rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis may help provide a better understanding as to why certain rheumatic diseases improve during pregnancy...Ostensen M, et al. Ann Rheum Dis. 2005;64:839-844
Tuesday May 17, 2005
Corgentech's Inhibitor of NF-kB Reduces Inflammatory Response in Preclinical Model
Corgentech Inc. reported that NF-KappaB Decoy (NF-kB Decoy), a DNA-based drug candidate, has shown activity in preclinical models against atopic dermatitis, as measured by the reduced recruitment and proliferation of proinflammatory cells, and by the induction of apoptosis in cells related to inflammation.
Tuesday May 17, 2005
Medarex's Fully Human Monoclonal Antibody Targeting IP-10 (CXCL10) Starts Phase I Trial
Medarex Inc, announced the initiation of a multicenter, single-dose, dose-escalation, 32-patient Phase I clinical trial for MDX-1100, a fully human monoclonal antibody targeting the chemokine IP-10 (CXCL10), for the treatment of ulcerative colitis.
Tuesday May 17, 2005
Avidex Inhibitor of T Cell Costimulation Enters Phase I Clinical Trials
Avidex Ltd announced the start of Phase I clinical testing for RhuDexR, a small molecule, orally available, immunosuppressant and anti-inflammatory agent, for the treatment of rheumatoid arthritis.
Thursday May 05, 2005
Etanercept May Not Be Optimal for Treatment of Systemic Onset JRA
New results showing that more than 50% of SOJRA patients have a poor or limited response to etanercept suggest that alternative therapies are needed...Kimura Y, et al. J Rheumatol. 2005;32:935-942.
Friday Apr 29, 2005
Interleukin-1 Blockade Potentiates Morphine Efficacy and Prevents Tolerance
New results in mice indicate that inhibition of IL-1 signaling may also prevent side effects by allowing the use of lower doses of opiates...Shavit Y, et al. Pain 2005;115:50-59.
Friday Apr 15, 2005
Small Interfering RNA Suppresses Inflammation in Mouse Model of Arthritis
Local administratipon of TNF-α-directed siRNA inhibits collagen-induced arthritis in mice, suggesting a potential treatment strategy for RA...Schiffelers, RM. Arthritis Rheum. 2005;52:1314-1318.
Friday Apr 08, 2005
Thalidomide May Play a Role in Treatment of Refractory Radiculopathic Pain
Banned from use in the 1960s due to its teratogenic effects, thalidomide is being reexamined as a treatment for inflammatory and other types of disorders... Presented at the 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Massachusetts
Wednesday Mar 23, 2005
IL-1 Blocker Anakinra Safe and Effective in Small Study of Severe Lupus Arthritis Patients
Accumulating evidence suggests that anakinra may find a niche in IL-1-driven diseases such as juvenile arthritis, adult onset Still's disease, and severe lupus arthritis...Ostendorf B, et al. Ann Rheum Dis. 2005;64:630-633.
Wednesday Mar 09, 2005
Development of Antibodies Targeting Interferon-± and the Type I Interferon Receptor 1 Underway
The type I interferon system has been implicated in the development and maintenance of abnormal autoimmune responses.
Monday Dec 13, 2004
Synovial Tissue Interleukin-18 Expression Correlates With Inflammatory Arthritis Disease Activity
New study underscores the important proinflammatory role of IL-18 in the pathophysiology of inflammatory arthritis, and suggests that treatment that inhibits or neutralizes endogenous IL-18 may become an effective tool in controlling synovial tissue inflammation&Rooney T, et al. Ann Rheum Dis. 2004;63:1393-1398.
|
